Skip to content
header-laboratoire03

Group Overview

With a 160-year heritage, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets.  We have approximately 9 000 employees at 69 established offices in over 50 countries and we improve the health of patients in more than 150 countries through our high quality, affordable products.

Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments.  Our key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands that include Anaesthetics and Thrombosis products.

Our manufacturing capabilities cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients. We operate 23 manufacturing facilities across 15 sites and we hold international manufacturing approvals from some of the most stringent global regulatory agencies including, among others, the United States Food and Drug Administration, the Australian Therapeutic Goods Administration and the European Directorate for the Quality of Medicines.

Our Global Presence

Our Business Segments

We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through our key business segments:

Commercial Pharmaceuticals

Regional Brands – a widely diverse segment comprising predominantly leading domestic brands in the
Sub-Saharan Africa, Australasia and Latin American territories.

Contribution to
Group revenue

45%

Sterile Focus Brands – focused on niche, sterile products comprising our Anaesthetics Brands and Thrombosis Brands.

Anaesthetics – includes a broad range of general anaesthetics, muscle relaxants as well as a number of local anaesthetics including topical agents.

Thrombosis – comprises a broad range of specialist injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors and heparin derivatives.

Contribution to
Group revenue

27%

Manufacturing

Contract and supply of chemical and biochemical APIs and finished dose form pharmaceuticals for third parties

Contribution to
Group revenue

28%

Scroll To Top